ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,519,334 | -30.5% | 210,921 | -10.0% | 0.02% | -37.8% |
| Q2 2023 | $10,816,009 | -34.9% | 234,468 | -43.4% | 0.04% | -37.3% |
| Q1 2023 | $16,610,503 | +224245.0% | 414,227 | +159.2% | 0.06% | +118.5% |
| Q4 2022 | $7,404 | -99.9% | 159,819 | -15.5% | 0.03% | -10.0% |
| Q3 2022 | $7,830,000 | +1169.0% | 189,094 | +1727.0% | 0.03% | +1400.0% |
| Q2 2022 | $617,000 | -29.8% | 10,350 | -1.0% | 0.00% | -33.3% |
| Q4 2021 | $879,000 | +7.1% | 10,454 | +14.8% | 0.00% | 0.0% |
| Q3 2021 | $821,000 | -90.1% | 9,108 | -84.8% | 0.00% | -91.7% |
| Q4 2020 | $8,291,000 | – | 59,891 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |